{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:47:52Z","timestamp":1764308872942,"version":"3.41.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Over the past decade, the proportion of hepatitis C virus (HCV) genotypes (GT) 1 and 2 has decreased in almost all regions of China, while GT 3 and 6 have emerged as new challenges. GT 6 is unique in many respects, like high genetic variability and emerging resistant variants. This study aims to assess the efficacy of sofosbuvir (SOF)-based treatments in patients with GT 6 chronic hepatitis C (CHC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis was conducted on patients with GT 6 HCV infection, who were diagnosed between July 2018 and May 2023. All patients received a 12-week course of SOF-based treatments. The primary efficacy endpoint was sustained virologic response (SVR), which is defined as having undetectable HCV RNA at 12 weeks after treatment completion (SVR12). The efficacy data for SVR12 were analyzed using both the evaluated population (EP) and per-protocol population (PP). For the PP populations, efficacy data were stratified using Forrester plots.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 201 patients were included in the study. In PP population, the end of treatment virological response rate was 99.48% (190\/191), the SVR12 rate was 99.31% (143\/144), and the SVR24 rate was 100.00% (75\/75). Only one patient with genotype 6a experienced a relapse 12 weeks after the completion of treatment, but her HCV RNA was undetectable both at the end of treatment and 24 weeks after the end of treatment. Additionally, the normalization rates of alanine transaminase (ALT) and aspartate aminotransferase (AST) were significantly higher at the end of treatment (EOT) compared to baseline (27.36% vs. 93.03%, 36.32% vs. 95.02%, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). Significant improvements were observed in the levels of total bilirubin, ALT, AST, albumin, globulin, albumin\/globulin ratio, gamma-glutamyl transferase, alkaline phosphatase, platelet, fibrosis-4 (FIB-4), and aspartate transaminase to platelet ratio index (APRI) between baseline and EOT (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SOF-based treatments achieved high virological and biochemical response rates in patients with HCV GT 6 infection.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1462706","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T04:19:52Z","timestamp":1732594792000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of sofosbuvir-based treatments for patients with hepatitis C virus genotype 6 infection: a real-world study from East China"],"prefix":"10.3389","volume":"11","author":[{"given":"Fan-Rong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ting","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He-Qing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Tao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Lan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Rong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"year":"2024","key":"ref1"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3748\/wjg.v29.i6.949","article-title":"Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C","volume":"29","author":"Brzd\u0119k","year":"2023","journal-title":"World J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamainternmed.2022.5699","article-title":"Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic Hepatitis C","volume":"183","author":"Ogawa","year":"2023","journal-title":"JAMA Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12879-021-06053-3","article-title":"Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort","volume":"21","author":"Quaranta","year":"2021","journal-title":"BMC Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/17474124.2021.1877136","article-title":"Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals","volume":"15","author":"Nevola","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fphar.2020.00710","article-title":"Efficacy and safety of direct-acting antiviral therapy in patients with chronic hepatitis C virus infection: a real-world single-center experience in Tianjin, China","volume":"11","author":"Xia","year":"2020","journal-title":"FPHAR"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/apt.14977","article-title":"Review article: novel antivirals for hepatitis C-sofosbuvir\/velpatasvir\/voxilaprevir, glecaprevir\/pibrentasvir","volume":"48","author":"Pearlman","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1111\/liv.14537","article-title":"Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts","volume":"40","author":"Mangia","year":"2020","journal-title":"Liver Int"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.2147\/IDR.S312902","article-title":"Sofosbuvir-based therapies achieved satisfactory Virological response in Chinese individuals with genotypes 3 and 6 infections: a real-world experience","volume":"14","author":"Tang","year":"2021","journal-title":"Infect Drug Resist"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s40121-022-00666-0","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir as a hepatitis C virus infection salvage therapy in the real world: a systematic review and meta-analysis","volume":"11","author":"Xie","year":"2022","journal-title":"Infect Dis Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40249-023-01106-y","article-title":"Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Chinese mainland and a phylogenetic analysis","volume":"12","author":"Tang","year":"2023","journal-title":"Infect Dis Poverty"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/ajg.2017.123","article-title":"HCV genotype 6 increased the risk for hepatocellular carcinoma among Asian patients with liver cirrhosis","volume":"112","author":"Lee","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3760\/cma.j.cn501113-20200525-00271","article-title":"A real-world study of sofosbuvir-based drug treatment for hepatitis C virus genotype 6 infection in Hainan region of China","volume":"29","author":"Wang","year":"2021","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"8872120","DOI":"10.1155\/2020\/8872120","article-title":"Efficacy and safety of sofosbuvir-based direct-acting antiviral agents treatment for patients with genotype 3\/6 Hepatitis C virus infection","volume":"2020","author":"Mei","year":"2020","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/apt.15100","article-title":"Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection","volume":"49","author":"Mettikanont","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1038\/emi.2017.77","article-title":"Hepatitis C virus genotypes and subtypes circulating in mainland China","volume":"6","author":"Chen","year":"2017","journal-title":"Emerg Microbes Infect"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.12998\/wjcc.v10.i14.4480","article-title":"Distribution and changes in hepatitis C virus genotype in China from 2010 to 2020","volume":"10","author":"Yang","year":"2022","journal-title":"World J Clin Cases"},{"year":"2022","key":"ref22"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","volume":"71","author":"Llaneras","year":"2019","journal-title":"J Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3760\/cma.j.issn.1007-3418.2020.02.005","article-title":"Highlights of the guidelines of prevention and treatment for hepatitis C (2019 version)","volume":"28","author":"Rao","year":"2020","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad319","article-title":"Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating Hepatitis C virus infection","author":"Bhattacharya","year":"2023","journal-title":"Clin Infect Dis"},{"key":"ref26","first-page":"41","article-title":"vision","volume":"2023","year":"2022","journal-title":"Chin J Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series(\u2606)","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae479","article-title":"Primary care guidance for providers of care for persons with human immunodeficiency virus: 2024 update by the HIV medicine Association of the Infectious Diseases Society of America","author":"Horberg","year":"2024","journal-title":"Clin Infect Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/jgh.15324","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir in the treatment of patients with genotype 3 and 6 chronic hepatitis C","volume":"53","author":"Xiaoting","year":"2023","journal-title":"J Wenzhou Med Univ"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","article-title":"A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial","volume":"7","author":"Solomon","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e0290235","DOI":"10.1371\/journal.pone.0290235","article-title":"Metabolic, renal, and hematological changes in chronic hepatitis C patients achieving rapid virologic response after 12 weeks of direct-acting antiviral treatment: a prospective cohort study","volume":"18","author":"Thi Thu","year":"2023","journal-title":"PLoS One"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e29686","DOI":"10.1002\/jmv.29686","article-title":"Comparison of diagnostic performance among Abbott RealTime HCV genotyping II, Abbott HCV genotype plus RUO, and Roche Cobas HCV genotyping assays for hepatitis C virus genotyping","volume":"96","author":"Chang","year":"2024","journal-title":"J Med Virol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1462706\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T04:19:57Z","timestamp":1732594797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1462706\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":35,"alternative-id":["10.3389\/fmed.2024.1462706"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1462706","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"article-number":"1462706"}}